Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones?

Hepatology Research

Volumn 41, Issue 7, 2011, Pages 687-695

  Ratziu, Vlad ^a   Pienar, Loredana ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Fibrosis; Glitazones; Insulin resistance; Insulin sensitizing drugs; Non alcoholic steatohepatitis; Steatosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINOTRANSFERASE; GLITAZONE DERIVATIVE; INSULIN SENSITIZING AGENT; PIOGLITAZONE; ROSIGLITAZONE;

AMINOTRANSFERASE BLOOD LEVEL; CARDIOTOXICITY; CHRONIC LIVER DISEASE; DRUG SAFETY; FRACTURE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER DISEASE; LIVER FIBROSIS; METABOLISM; NONALCOHOLIC FATTY LIVER; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 79959777881     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00825.x     Document Type: Review

References (52)

1. Ratziu V, Bonyhay L, Di Martino V etal. Survival, liver failure, and hepatocellular carcinoma in obesityrelated cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
2. Paradis V, Zalinski S, Chelbi E etal. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851-9.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
4. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
5. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
6. Nayak NC, Vasdev N, Saigal S, Soin AS. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol 2010; 41: 425-30.
7. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40: 578-84.
8. Soderberg C, Stal P, Askling J etal. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
9. Dam-Larsen S, Franzmann M, Andersen IB etal. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-5.
10. Ong J, Pitts A, Younossi Z. Increased overall mortality and liver-related mortality in nonalcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
11. Gastaldelli A, Kozakova M, Hojlund K etal. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-44.
12. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.
13. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-9.
14. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
15. Fabbrini E, Magkos F, Mohammed BS etal. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 2009; 106: 15430-5.
16. Fracanzani AL, Valenti L, Bugianesi E etal. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8.
17. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000.
18. Yamaguchi K, Yang L, McCall S etal. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-74.
19. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-9.
20. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.
21. Petta S, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009; 41: 615-25.
22. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 545-63.
23. Ratziu V, Zelber-Sagi S. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 667-88.
24. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-95.
25. Gastaldelli A, Harrison SA, Belfort-Aguilar R etal. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50: 1087-93.
26. Bugianesi E, Pagotto U, Manini R etal. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-504.
27. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 2007; 9: 640-7.
28. Mazzone T, Meyer PM, Feinstein SB etal. Effect of pioglitazone compared with glimepiride on carotid intimamedia thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-81.
29. Nissen SE, Nicholls SJ, Wolski K etal. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-73.
30. Sanyal AJ, Mofrad PS, Contos MJ etal. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
31. Belfort R, Harrison SA, Brown K etal. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
32. Ratziu V, Giral P, Jacqueminet S etal. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
33. Aithal GP, Thomas JA, Kaye PV etal. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84.
34. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010; 362: 1675-85.
35. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
36. Promrat K, Lutchman G, Uwaifo GI etal. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96.
37. Ratziu V, Charlotte F, Bernhardt C etal. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-53.
38. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010; 52: 2206-15.
39. Neuschwander-Tetri BA. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr Gastroenterol Rep 2010; 12: 49-56.
40. Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2005; 3: 384-9.
41. Lutchman G, Modi A, Kleiner DE etal. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-9.
42. Lutchman G, Promrat K, Kleiner DE etal. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006; 4: 1048-52.
43. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
44. Home PD, Pocock SJ, Beck-Nielsen H etal. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38.
45. Home PD, Pocock SJ, Beck-Nielsen H etal. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-35.
46. Kahn SE, Haffner SM, Heise MA etal. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
47. Gerstein HC, Yusuf S, Bosch J etal. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
48. Dormandy JA, Charbonnel B, Eckland DJ etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
49. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-8.
50. Miyazaki Y, Mahankali A, Matsuda M etal. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91.
51. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19: 129-37.
52. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-9.